amifampridine has been researched along with Essential Tremor in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Essential Tremor: A relatively common disorder characterized by a fairly specific pattern of tremors which are most prominent in the upper extremities and neck, inducing titubations of the head. The tremor is usually mild, but when severe may be disabling. An autosomal dominant pattern of inheritance may occur in some families (i.e., familial tremor). (Mov Disord 1988;13(1):5-10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lorenz, D | 1 |
| Hagen, K | 1 |
| Ufer, M | 1 |
| Cascorbi, I | 1 |
| Deuschl, G | 1 |
| Volkmann, J | 1 |
1 trial available for amifampridine and Essential Tremor
| Article | Year |
|---|---|
No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Topics: 4-Aminopyridine; Adult; Amifampridine; Cross-Over Studies; Dose-Response Relationship, Drug; Double- | 2006 |